doxycycline + pentoxifylline + nitazoxanide

This combination therapy, investigated by Tanta University, consists of doxycycline, pentoxifylline, and nitazoxanide. Doxycycline is a second-generation tetracycline antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit. Pentoxifylline is a xanthine derivative and non-selective phosphodiesterase inhibitor used for its vasoactive and immunomodulatory effects, specifically its ability to inhibit TNF-alpha production. Nitazoxanide is a thiazolide antimicrobial that interferes with the pyruvate:ferredoxin oxidoreductase (PFOR) enzyme-dependent electron transfer reaction, essential for anaerobic metabolism. The combination is being evaluated in a Phase 2/3 trial for the treatment of untreated gonorrhea and chlamydia infections in sexually active men to determine if the triple therapy is superior to doxycycline monotherapy.

Other names

Doxycycline, Pentoxifylline, and Nitazoxanide for STIs in Men